Glioblastoma (GBM) is a highly malignant type of primary brain tumor with a high mortality
rate. Although the current standard therapy consists of surgery followed by radiation and …

Immune checkpoint inhibitors (ICI s) block CTLA‐4, PD‐1 and PD‐L1, or other molecules
that control antitumour activities of lymphocytes. These products are associated with a broad …

Severe and prolonged lymphopenia frequently occurs in patients with glioblastoma after
standard chemoradiotherapy and has been associated with worse survival, but its …

Immune checkpoint inhibitor therapy has revolutionized the treatment of advanced
malignancies in recent years. Numerous reports have detailed the myriad of possible …

Although the ever-increasing number of cancer patients pose substantial challenges
worldwide, finding a treatment with the highest response rate and the lowest number of side …

Survival of glioma (GBM) patients treated with the current standard of care remains dismal.
Immunotherapeutic approaches that harness the cytotoxic and memory potential of the host …

The development of immune checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte
antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed cell death …

Glioma accounts for the majority of human brain tumors. With prevailing treatment regimens,
the patients have poor survival rates. In spite of current development in mainstream glioma …

Gliomas are the most common type of brain tumor that occur in adults and children.
Glioblastoma multiforme (GBM) is the most common, aggressive form of brain cancer in …

Two series of novel o-(biphenyl-3-ylmethoxy) nitrophenyl compounds (A1–31 and B1–17)
were designed as programmed cell death protein 1 (PD-1)/PD-ligand 1 (PD-L1) inhibitors …